Type of Study: Clinical Trial

Sponsor / Support: EORTC, Bayer

Primary Objectives: The primary objective of the trial is to assess if upfront combination of enzalutamide and Ra223 improves radiological progression-free survival (rPFS1) compared to enzalutamide single agent in castration resistant prostate cancer (CRPC) patients metastatic to bone

Design: This is a randomized phase III open label trial. 

Sample Size: 560 patients

Principal Investigator: Andrey Soares (Steering Committee – LACOG)

Countries LATAM: Brazil